Clinical Trials Logo

Severe clinical trials

View clinical trials related to Severe.

Filter by:
  • None
  • Page 1

NCT ID: NCT02184442 Completed - Clinical trials for Calcific Aortic Stenosis

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B

PARTNERII B
Start date: March 9, 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of the SAPIEN XTâ„¢ THV with the associated delivery system for inoperable patients with severe symptomatic native aortic stenosis.

NCT ID: NCT00457613 Completed - Shock Clinical Trials

Effects of Alkaline Phosphatase on Renal Function in Septic Patients

Start date: November 2004
Phase: Phase 2
Study type: Interventional

Septic shock is the most common cause of death in patients requiring intensive care. The kidney is one of the first organs to fail, stressing the importance to search for clinical interventions that may protect the kidneys during sepsis. Alkaline phosphatase functions as a host defence molecule and is present in many cells and organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for mammals which acts as a partial antagonist on the LPS receptor complex. In several animal studies, administration of alkaline phosphatase attenuates the inflammatory response and reduces mortality. It is unknown whether these results can be extrapolated to septic patients . We studied the effects of alkaline phosphatse administration on kidney damage and function in patients with severe sepsis or septic shock.